5 completed, 2 unknown, 2 withdrawn, 1 recruiting. 4 Phase 1, 3 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 3 | Withdrawn 2, Unknown 1 |
| Phase 3 | 2 | Recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow oplunofusp: new trials by email Literature Review of oplunofusp trials Research Report on oplunofusp
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic Convalescent Plasma Transfusion, Hydroxychloroquine, DAS181 - COVID-19 | Unknown | Qassim University | 200 | 2020-07-25 | 2020-07-07 | |
| DAS181 for STOP COVID-19 DAS181, Placebo - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Ansun Biopharma, Inc. | 2020-07-25 | 2020-08-11 | |
| DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) DAS181, Placebo - Influenza Infection, SAD-RV Infection and COVID-19 | Phase 2 | Unknown | Ansun Biopharma, Inc. | 280 | 2020-07-01 | 2020-07-09 |
| DAS181 for Severe COVID-19: Compassionate Use DAS181 - COVID-19 | Not applicable | Completed | Renmin Hospital of Wuhan University | 4 | 2020-03-06 | 2020-05-05 |
| Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study DAS181, Placebo, DAS181 COVID-19 - Lower Respiratory Tract Infection, Parainfluenza | Phase 3 | Recruiting | Ansun Biopharma, Inc. | 274 | 2019-05-23 | 2026-06-23 |
| Influenza Antiviral DAS-181-F04 in Healthy Adults DAS181, Placebo - Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 9 | 2011-08-12 | 2017-04-07 |
| DAS181 in Patients With Parainfluenza DAS181, Placebo - Parainfluenza Infection | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-07-14 | 2019-12-17 | |
| Influenza Antiviral DAS181-F03 Placebo, DAS181 - Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2010-11-01 | 2013-07-19 |
| DAS181 Single Dose Escalation Study in Healthy Adults DAS181, Lactose - Healthy | Phase 1 | Completed | Ansun Biopharma, Inc. | 45 | 2009-05-18 | 2019-08-02 |
| Single Dose Escalating Study of DAS181 in Adults DAS181, Placebo - Influenza | Phase 1 | Completed | Ansun Biopharma, Inc. | 36 | 2007-10-01 | 2009-01-08 |
COVID-19 (5) · Influenza, Human (4) · Coronavirus Infections (2) · Hypoxia (2) · Paramyxoviridae Infections (2) · Fever (1) · Infections (1) · Respiratory Aspiration (1) · Respiratory Tract Diseases (1)
Ansun Biopharma, Inc. (5) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Qassim University (1) · Renmin Hospital of Wuhan University (1)
United States (5) · China (3) · Australia (1) · Italy (1) · South Korea (1) · Taiwan (1)
Jennifer Ho, MD, PhD (2) · Richard T Davey, M.D. (1) · Ronald B Moss, MD (1) · Zuojiong Gong, MD (1)
2018 (1)